Author: BusinessWire

CLEVELAND–(BUSINESS WIRE)–$ATHX #Athersys–Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® cell therapy, today announced that it has entered into a cooperation agreement with HEALIOS K.K. (“Healios”), the Company’…

CLEVELAND–(BUSINESS WIRE)–$ATHX #Athersys–Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® cell therapy, today announced that it has entered into a cooperation agreement with HEALIOS K.K. (“Healios”), the Company’…

CLEVELAND–(BUSINESS WIRE)–$ATHX #Athersys–Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® cell therapy, today announced that it has entered into a cooperation agreement with HEALIOS K.K. (“Healios”), the Company’…

REBLOZYL®, an erythroid maturation agent, is the first and only of its kind approved for use in Canada
MONTREAL–(BUSINESS WIRE)–Bristol Myers Squibb Canada (BMS) and Acceleron Pharma Inc. announced today that Health Canada has approved REBLOZYL® (lu…

PALO ALTO, Calif.–(BUSINESS WIRE)–#biotech–Medable Inc., the leading cloud platform for patient-centered drug development, today announced the addition of four new members to its Patient Advisory Council (PAC). The PAC advises Medable and its biopha…

Members include preeminent international scientific and clinical thought leaders in gene therapy, diseases of the central nervous system, and drug discovery and development

Collective experience will provide invaluable research, clinical insights and…

FDA stated it is not currently planning to hold an advisory committee meeting

Potential for Vicineum to be a best-in-class treatment with projected peak revenue of $1B-$3B globally, $400M-$900M in the US

Company to hold conference call at 8am ET
CAM…

Pro forma Cash Expected to Fund Manufacturing, Regulatory and Commercial Readiness Preparations for Omidubicel and the Advancement of GDA-201 Clinical Development
BOSTON–(BUSINESS WIRE)–Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy compa…

CAMBRIDGE, Mass.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE) announced today that the company has placed its Phase 1/2 (HGB-206) and Phase 3 (HGB-210) studies of LentiGlobin gene therapy for sickle cell disease (SCD) (bb1111) on a temporary sus…

-ADG20 is uniquely engineered to maximize potency, duration of effect, and ease of use in the community setting, and has shown outstanding manufacturability to meet global demand-

-ADG20 binds to a highly conserved region of the spike protein not tar…